Director dealings
Portfolio
Charting
Alerts

Few people are better placed to evaluate a company's prospects than those who actually run it, which is why many investors regard directors' share dealings as a key indicator of future prospects.

Transactions

Dealing date
Company
& ticker
Name & title
Number
of shares
Deal size
Purchase
17 May 2013		GlaxoSmithKline PLC
GSK:LSE		Sir Andrew Witty
Chief Executive Officer		2153.66kGBP
Purchase
17 May 2013		Marston's PLC
MARS:LSE		P Dalzell
--		10,00014.72kGBP
Purchase
17 May 2013		Ocado Group PLC
OCDO:LSE		Sir Stuart Rose
Chairman		452,2849.05kGBP
Purchase
17 May 2013		Universal Health Services Inc
UHS:NYQ		John H. Herrell
--		3,750113.70kUSD
Purchase
17 May 2013		Universal Health Services Inc
UHS:NYQ		John H. Herrell
--		3,750138.56kUSD
Purchase
17 May 2013		Universal Health Services Inc
UHS:NYQ		John H. Herrell
--		7,500327.53kUSD
Purchase
17 May 2013		Universal Health Services Inc
UHID:QBB		John H. Herrell
--		3,750113.70kUSD
Purchase
17 May 2013		Universal Health Services Inc
UHID:QBB		John H. Herrell
--		3,750138.56kUSD
Purchase
17 May 2013		Universal Health Services Inc
UHID:QBB		John H. Herrell
--		7,500327.53kUSD
Purchase
17 May 2013		Wolfson Microelectronics PLC
WLF:LSE		R K Graham
--		22,44650.00kGBP
1-10 of 1,107 results
12345

Latest director dealing news

May 19 2013 04:31 BST
Yesterday's stars are today's crooks
Another week, another fund manager arrested for alleged insider trading. This time around it is a former star manager at BlackRock, the world's largest investment house. Mark Lyttleton, 41, and a 37-year-old female relative, reported to be his wife, were detained on April 30 and questioned by the UK's Financial
May 17 2013 22:29 BST
SAC changes stance on insider trade probe
SAC Capital, the $15bn hedge fund at the heart of a wide-ranging probe into insider trading, on Friday told investors that its co-operation with the investigation was "no longer unconditional". The cryptic language in a letter to investors is a change from previous communications, in which the hedge fund run
May 17 2013 18:38 BST
UK directors' deals: Ideagen, Treatt, Quindell, Hikma
Three directors and a senior manager gave a vote of confidence in Ideagen last Friday making the first director trades as the software group prepares to mark a year since listing last July. Early investors have notched up returns of around 25 per cent but the shares are shy of
May 13 2013 18:10 BST
Level Global's Anthony Chiasson given more than six years in jail
Anthony Chiasson, co-founder of defunct hedge fund Level Global, has been sentenced to nearly six and a half years in prison for his role in a $70m insider trading scheme. Chiasson, who helped set up the New York firm after leaving SAC Capital, was convicted in December on charges of
Director dealing news

Latest corporate regulatory announcements

Time & dateCompanyHeadlineSource
20 May 2013
5:48 PM		ITE Group PLC
ITE:LSE		Director/PDMR ShareholdingRNS
20 May 2013
5:46 PM		ITE Group PLC
ITE:LSE		Director/PDMR ShareholdingRNS
20 May 2013
5:37 PM		Oakley Capital Investments Limited
OCL:LSE		Director/PDMR ShareholdingRNS
20 May 2013
5:21 PM		Jardine Lloyd Thompson Group PLC
JLT:LSE		Director/PDMR ShareholdingRNS
20 May 2013
4:51 PM		Kier Group PLC
KIE:LSE		Director/PDMR ShareholdingRNS
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.